Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q2 2020 · 10-Q
Revenue$42.89M$42.89M−77.6% vs Q2 2019 Net Income-$85.31M-$85.31MN/M vs Q2 2019 EPS Diluted-$0.95-$0.95N/M vs Q2 2019 Operating Income-$85,137,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$148,939,000N/M Margins · derivedOperating margin-198.5%−257.4 pt vs Q2 2019
Net margin-198.9%−259.5 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 6, 2020 · 37 d after period end